Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells [7]

Leukemia

Volumn 20, Issue 9, 2006, Pages 1629-1632

  Wehner, R ^a   Wendisch, M ^a   Schakel K ^a   Bornhauser M ^a   Platzbecker, U ^a   Mohr, B ^a   Temme, A ^a   Bachmann, M ^a   Rieber, E P ^a   Schmitz, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; IMATINIB; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BLOOD SAMPLING; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; IN VITRO STUDY; LETTER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 33747610930     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404315     Document Type: Letter

References (10)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
2. Sato N, Narita M, Takahashi M, Yagisawa K, Liu A, Abe T et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003; 21: 67-75.
3. Westers TM, Janssen JJ, Houtenbos I, Snoijs NC, van de Loosdrecht AA, Ossenkoppele GJ. Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens. Leukemia 2006; 20: 154-157.
4. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Soulier J, Mooney N et al. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol 2006; 79: 747-756.
5. Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538-544.
6. Appel S, Rupf A, Weck MM, Schoor O, Brümmendorf TH, Weinschenk T et al. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways. Clin Cancer Res 2005; 11: 1928-1940.
7. Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
8. Schäkel K, von Kietzell M, Hänsel A, Ebling A, Schulze L, Haase M et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006; 24: 767-777.
9. Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004; 103: 4666-4668.
10. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005; 365: 657-662.